Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting
HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations
Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting
Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?
Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…Abstract Number: 1289 • 2017 ACR/ARHP Annual Meeting
Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Classification of chronic vasculitis to clinically or etiologically meaningful groups has been challenging. In 2008, the 1990 ACR classification criteria for GPA was adapted…Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting
New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis
Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…Abstract Number: 1778 • 2017 ACR/ARHP Annual Meeting
Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Pneumocystis jiroveciipneumonia (PCP) is a fatal complication in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, the current situation of prophylactic treatment of PCP and its…Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 20
- Next Page »